Confidence Intervals Favored Over P-Values In FDA Clinical Studies Guidance
Executive Summary
P-values are not an adequate measure of uncertainty in describing the clinical outcome of a treatment relative to a comparator, FDA maintains in a draft guidance on the Clinical Studies section of labeling.
You may also be interested in...
Rx Label Format Changes Should Be Phased In Without "Highlights" - PhRMA
FDA's prescription drug labeling initiative should proceed in areas where there is consensus between the agency and the pharmaceutical industry, the Pharmaceutical Research & Manufacturers of America said in comments on the proposed rule.
Rx Label Format Changes Should Be Phased In Without "Highlights" - PhRMA
FDA's prescription drug labeling initiative should proceed in areas where there is consensus between the agency and the pharmaceutical industry, the Pharmaceutical Research & Manufacturers of America said in comments on the proposed rule.
Pregnancy Labeling Updates Could Include Published Data, Not Just Trials
FDA plans to rely on data other than randomized controlled studies when it updates drug labels under the forthcoming pregnancy labeling rule.